Bruker AXS GmbH announced today the closing of its acquisition of JUWE Laborgeraete GmbH in Viersen, Germany. The renamed Bruker JUWE GmbH will operate under its previous experienced management with a focus on rapid growth in combustion analysis for metals analysis. During 2008, Bruker JUWE will be relocated to Kalkar, Germany, where together with spark-OES specialist Bruker Quantron, it will be part of the new Bruker Elemental Analysis Center of Excellence.
JUWE has serviced, and later on developed, manufactured and sold combustion analysis (CA) systems for elemental analysis since 1997, primarily for the metal production, chemical and pharmaceutical industries. JUWE’s high-quality CA products complement Bruker’s X-ray fluorescence (XRF) and optical emission spectroscopy (OES) product lines in the field of elemental analysis.
ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)
Bruker BioSciences Corporation in Billerica, Massachusetts is the parent company of Bruker AXS Inc., Bruker Daltonics Inc. and Bruker Optics Inc. For more information: www.bruker-biosciences.com
CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended Dec. 31, 2006, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.
Contacts:
Michael Willett, +1 978-663-3660,
ext. 1411
Investor Relations Officer
ir@bruker-biosciences.com
